Astrana Health
Astrana Health, Inc.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$3.2B
Operating marginCalculated
2.5%
Net assets to total assetsCalculated
35.1%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
2.5%
Growth (revenue, 4-year average)
★★★★★position among all companies
42.4%
Capital efficiency
★★☆☆☆position among all companies
2.9%
Revenue and profit
Performance, financial position and capital allocation
Astrana Health
Recent performance trends
Astrana Health
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$0.8 billion | US$1.1 billion | US$1.4 billion | US$2.0 billion | US$3.2 billion |
| Operating income | US$98.18 million | US$0.1 billion | US$84.61 million | US$89.35 million | US$78.53 million |
| Net income | US$68.92 million | US$45.17 million | US$60.72 million | US$43.15 million | US$22.49 million |
| Total assets | US$0.9 billion | US$1.0 billion | US$0.9 billion | US$1.4 billion | US$2.2 billion |
| Shareholders' equity | US$0.4 billion | US$0.5 billion | US$0.6 billion | US$0.7 billion | US$0.8 billion |
| Net cash provided by (used in) operating activities | US$70.33 million | US$82.13 million | US$68.23 million | US$52.20 million | US$0.1 billion |
| Net cash provided by (used in) investing activities | US$16.54 million | US$-7.11 million | US$-65.52 million | US$-0.2 billion | US$-0.5 billion |
| Net cash provided by (used in) financing activities | US$-47.75 million | US$-20.09 million | US$3.42 million | US$0.1 billion | US$0.6 billion |
| Cash and cash equivalents | US$0.2 billion | US$0.3 billion | US$0.3 billion | US$0.3 billion | US$0.4 billion |
Revenue scale in the same industry
Astrana Health
Engineering, accounting, research and management services: 11 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Iqvia HoldingsFY Dec 2025 US$16.3B
- 2 AecomFY Sep 2025 US$16.1B
- 3 Booz Allen Hamilton HoldingFY Mar 2026 US$11.2B
- … 5 companies
- 9 Charles River Laboratories InternationalFY Dec 2025 US$4.0B
- 10 FTI ConsultingFY Dec 2025 US$3.8B
- 11 Astrana HealthThis companyFY Dec 2025 US$3.2B
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$10.11 million | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$0.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.1 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$45.75 million | Consolidated | Disclosed |
| Dividends paid | US$7.88 million | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$0.8 billion | Consolidated | Disclosed |
| Non-controlling interests | US$14.01 million | Consolidated | Disclosed |
| Net assets | US$0.8 billion | Consolidated | Disclosed |
| Net sales | US$3.2 billion | Consolidated | Disclosed |
| Operating income | US$78.53 million | Consolidated | Disclosed |
| Net income | US$22.49 million | Consolidated | Disclosed |
| Total assets | US$2.2 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$25.60 million | Consolidated | Disclosed |
| Operating margin | 2.5% | Consolidated | Calculated |
| Net assets to total assets | 35.1% | Consolidated | Calculated |
| Net margin | 0.7% | Consolidated | Calculated |
| Return on equity | 2.9% | Consolidated | Calculated |